Celanese collaborates with Alessa Therapeutics for the advancement of oncology treatments

The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients

Aurobindo arm CuraTeQ receives Health Canada approval for bevacizumab biosimilar Bevqolva

Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market

Kapil Dev inaugurates Digital PET-CT and Nuclear Medicine Department at Mahajan Imaging & Labs

New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology

Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026

The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care

Zydus hits Keytruda biosimilar milestone with successful FYB206 trial, targets USFDA filing

Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets

Centivax launches first human trial of universal flu vaccine

AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer

The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)

Novartis to open Florida radioligand facility

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies

Astal signs LoI with Immuna Therapeutics

Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation